Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of postoperative adjuvant S-1 after curative esophagectomy for esophageal cancer
jRCT1060220042Recruiting
- Sponsor
- Shimane University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegafur in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC) and esophageal cancer, sponsored by Shimane University. Primary endpoint: Safety and feasibility of S-1 administration. Started Jul 2022; status: recruiting.
02
Drugs
tegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)esophageal cancer
Beyond the preview
Go deeper on jRCT1060220042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1060220042.